undamentalytics Newsletter
Sign in

Tonix Pharmaceuticals Holding Corp. (TNXP) stock

Add to watchlist

Add holding +

NASDAQ: TNXP Nasdaq Biotechnology Next results ~November 9, 2026

C Fundamentals grade

Tonix Pharmaceuticals Holding Corp. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$21

Forward price-to-sales vs peers

Base case. Range ~$21–$79. Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Tonix Pharmaceuticals Holding Corp. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders4 buying, 0 selling7 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds79 adding, 13 cuttingOf 16 active managers that changed their stake, 13 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Tonix Pharmaceuticals Holding files

Where Tonix Pharmaceuticals stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $29m, up 196.0% on a year earlier, faster than the 74.8% growth a quarter earlier. That growth ranks 19 of 122 among the biotechnology companies we cover. Free-cash-flow margin rose to -543.3% from -665.1% a year earlier. Operating margin widened to -568.4% from -838.0%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 2 financial-health checks. Our price-to-sales vs peers value is $4.47 a share.

Source: 10-Q filed August 10, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

Tonix Pharmaceuticals Holding Corp.'s trailing-twelve-month revenue grew 196.0% year on year, with a free-cash-flow margin of -543.3%. Where it stands out: change in growth rate of +121.2pp ranks 18 of 172 biotechnology companies we cover. Where it lags: days sales outstanding of 148 days ranks 86 of 100 biotechnology companies we cover.

Current signal Revenue growth accelerating: TTM revenue growth rose to 196.0% (+121.2pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 196.0% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Growth speeding up. The growth rate is 121.2 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 269.6 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.2bn.

Things to watch

  • Loss-making. Operating margin is -568.4%: costs exceed revenue.
  • Burning cash. Free cash flow was -543.3% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 27.3% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • Volatile shares. Over the past year the shares showed annualised volatility of 71% and a beta of 1.8 against the S&P 500.
  • Below peers: days sales outstanding. Days sales outstanding of 148 days ranks 86 of 100 biotechnology companies we cover (median 75 days).
  • Heavily shorted. 17.2% of the shares available to trade are sold short (3.5 days of average volume to cover).

Latest results: FY2026 Q2

Filed August 10, 2026
Earnings per share
-$2.47 against an average estimate of -$2.62: beat by 5.6%
Revenue
$14m, up 577.9% on a year earlier
Share reaction
-5.6% in the first session after the results on October 15, 2026, against -0.8% for the S&P 500
Next report
November 9, 2026; average EPS estimate -$2.24

Tonix Pharmaceuticals Holding's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.5%
  • 1 week-4.0%
  • 1 month-41.9%
  • This year-67.0%
  • 1 year-72.4%
  • 5 years-100.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$29.1M
Operating margin
-568.4%
Net margin
-548.6%

Growth

Revenue growth
+196.0%
Change in growth rate
+121.2 pts

Cash

Free cash flow (TTM)
-$158M
FCF margin
-543.3%
Stock pay % of revenue
27.3%

Earnings

Last results
October 15, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Announcement
  3. Announcement
  4. Announcement
  5. Leadership
  6. Results
  7. Announcement
  8. Leadership
  9. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Tonix Pharmaceuticals Holding Corp. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Tonix Pharmaceuticals Holding Corp. as an operating company, with every model that fits that kind of business. Cost of equity 11.2%: the 10-year Treasury yield (4.9%) plus a beta of 1.39 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$38 ~$21–$54 Left out: out of range vs price (7.34x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$21 ~$21–$79 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$21 ~$21–$79 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Tonix Pharmaceuticals Holding Corp. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202320242025
Share price$1280.00$33.00$15.62
Market value$10m$24m$133m
+ Net debt (− = net cash)−$14m−$90m−$208m
Enterprise value−$4m−$66m−$75m
Multiples
Price / sales 1.3x2.4x10.1x
Price / earnings ———
Price / free cash flow ———
EV / EBITDA ———

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 9, 2026, before the open. Analysts expect revenue of $16m and EPS of −$2.24 (range −$2.40 to −$2.15) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$9.78 +33% $56m +325%
Next −$6.82 +30% $111m +99%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −3.1% on 90 days ago. In the last 30 days, 1 analyst raised Tonix Pharmaceuticals Holding Corp.'s forecast and 0 cut it.

Consensus EPS forecast Tonix Pharmaceuticals Holding Corp., last 90 days
−$15.00 −$10.00 −$5.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$10.10 Current fiscal year, 60 days ago: −$9.95 Current fiscal year, 30 days ago: −$9.95 Current fiscal year, 7 days ago: −$9.95 Current fiscal year, Now: −$9.78 −$9.78 Next fiscal year, 90 days ago: −$7.80 Next fiscal year, 60 days ago: −$7.88 Next fiscal year, 30 days ago: −$7.88 Next fiscal year, 7 days ago: −$7.88 Next fiscal year, Now: −$6.82 −$6.82

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$10.10−$7.80
60 days ago −$9.95−$7.88
30 days ago −$9.95−$7.88
7 days ago −$9.95−$7.88
Now −$9.78−$6.82

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$2.62 −$2.47 +5.6%
Mar 2026 −$2.54 −$2.93 −15.3%
Dec 2025 −$2.94 −$3.98 −35.4%
Sept 2025 −$2.75 −$3.70 −34.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

4 analysts, Oct 2026
Buy4100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202644
  2. Sep 202633
  3. Aug 202644
  4. Jul 202644

Counts of recommendations published by analysts covering Tonix Pharmaceuticals Holding Corp., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
17.2%
of tradable shares
Days to cover
3.48
at average volume
Short interest, 1 month
+4%
to October 15, 2026
Held by institutions
57%
of shares
Held by insiders
0.2%
of shares
Employees
142
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
TNXP−47%−97%−84%−97%−53%−67%
Industry peers (median)−35%−56%−17%−28%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
TNXP33%17%17%25%42%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
TNXP−82%−98%−95%−99%−84%−73%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since October 29, 2015: 100% from December 29, 2015 to October 30, 2026. Getting back needed a 97756864894% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$5.10 – $19.89
From 52-week high
−74.1%
vs 50-day average
−45.1%
vs 200-day average
−58.5%
Volatility (1 year)
71%
Beta vs S&P 500
1.81

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±5.6%
After a week
6 up, 6 down
typical move ±12.0%
After a month
4 up, 7 down
typical move ±34.8%
Results releasedNext dayS&P 500 next day5 days21 days
October 15, 2026 −5.6% −0.8% −19.8% —
August 10, 2026 +2.6% −0.3% +5.2% +6.7%
May 11, 2026 −5.7% +0.1% +1.2% −22.2%
May 1, 2026 +0.8% −0.1% +9.0% −9.4%
March 13, 2026 +1.1% +0.4% +11.9% −0.4%
February 3, 2026 −5.6% −1.3% −7.6% −20.3%
November 10, 2025 +3.1% +1.8% −1.1% +16.2%
October 27, 2025 0.0% +1.4% −3.7% −27.8%
August 11, 2025 +28.5% +0.9% −13.8% −41.9%
July 25, 2025 +5.8% +0.4% −12.8% −22.7%
May 12, 2025 +7.2% +4.0% +41.3% +100.3%
April 25, 2025 −0.9% +0.8% +16.3% +115.2%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Tonix Pharmaceuticals Holding Corp. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Tonix Pharmaceuticals Holding Corp.
$0 $10M $20M $30M FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Revenue (TTM), FY24 Q2: $12.5M Revenue (TTM), FY24 Q3: $11.3M Revenue (TTM), FY24 Q4: $10.1M Revenue (TTM), FY25 Q1: $10M Revenue (TTM), FY25 Q2: $9.8M Revenue (TTM), FY25 Q3: $10.3M Revenue (TTM), FY25 Q4: $13.1M Revenue (TTM), FY26 Q1: $17.6M Revenue (TTM), FY26 Q2: $29.1M $29.1M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY24 Q2 $12.5M
FY24 Q3 $11.3M
FY24 Q4 $10.1M
FY25 Q1 $10M
FY25 Q2 $9.8M
FY25 Q3 $10.3M
FY25 Q4 $13.1M
FY26 Q1 $17.6M
FY26 Q2 $29.1M
Revenue growth, TTM YoY Tonix Pharmaceuticals Holding Corp.
-100% 0% 100% 200% FY25 Q2 FY25 Q3 FY25 Q4 FY26 Q1 FY26 Q2 Revenue growth, TTM YoY, FY25 Q2: -21.1% Revenue growth, TTM YoY, FY25 Q3: -8.8% Revenue growth, TTM YoY, FY25 Q4: 29.8% Revenue growth, TTM YoY, FY26 Q1: 74.8% Revenue growth, TTM YoY, FY26 Q2: 196.0% 196.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY25 Q2 -21.1%
FY25 Q3 -8.8%
FY25 Q4 29.8%
FY26 Q1 74.8%
FY26 Q2 196.0%
Operating margin (TTM) Tonix Pharmaceuticals Holding Corp.
-1500% -1000% -500% 0% FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Operating margin (TTM), FY24 Q2: -1237.3% Operating margin (TTM), FY24 Q3: -1253.7% Operating margin (TTM), FY24 Q4: -1354.3% Operating margin (TTM), FY25 Q1: -1308.7% Operating margin (TTM), FY25 Q2: -838.0% Operating margin (TTM), FY25 Q3: -970.0% Operating margin (TTM), FY25 Q4: -959.1% Operating margin (TTM), FY26 Q1: -861.2% Operating margin (TTM), FY26 Q2: -568.4% -568.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q2 -1237.3%
FY24 Q3 -1253.7%
FY24 Q4 -1354.3%
FY25 Q1 -1308.7%
FY25 Q2 -838.0%
FY25 Q3 -970.0%
FY25 Q4 -959.1%
FY26 Q1 -861.2%
FY26 Q2 -568.4%
FCF margin (TTM) Tonix Pharmaceuticals Holding Corp.
-800% -600% -400% -200% 0% FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 FCF margin (TTM), FY24 Q2: -606.7% FCF margin (TTM), FY24 Q3: -612.8% FCF margin (TTM), FY24 Q4: -604.8% FCF margin (TTM), FY25 Q1: -597.0% FCF margin (TTM), FY25 Q2: -665.1% FCF margin (TTM), FY25 Q3: -741.1% FCF margin (TTM), FY25 Q4: -787.5% FCF margin (TTM), FY26 Q1: -744.1% FCF margin (TTM), FY26 Q2: -543.3% -543.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q2 -606.7%
FY24 Q3 -612.8%
FY24 Q4 -604.8%
FY25 Q1 -597.0%
FY25 Q2 -665.1%
FY25 Q3 -741.1%
FY25 Q4 -787.5%
FY26 Q1 -744.1%
FY26 Q2 -543.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 8 10 13 29
Gross profit 3 2 6 24
EBITDA −114 −133 −124 −163
Operating income −118 −137 −126 −165
Net income −117 −130 −124 −160
Diluted EPS −$14720.25 −$176.60 −$14.57 —
Growth (year on year)
Revenue — +29.9% +29.8% +196.0%
Margins
Gross margin 39.0% 23.1% 49.3% 83.8%
EBITDA margin <−999% <−999% −944.4% −561.4%
Operating margin <−999% <−999% −959.1% −568.4%
Net margin <−999% <−999% −946.2% −548.6%
Free-cash-flow margin <−999% −604.8% −787.5% −543.3%
Cash flow
Cash from operations −102 −61 −100 −153
Capital spending 8 0 3 5
Free cash flow −110 −61 −103 −158
Stock-based pay 9 5 6 8
Free cash flow after stock pay −119 −66 −109 −166
Balance sheet
Cash 25 99 208 176
Total debt 11 9 — 0
Net debt (negative = net cash) −14 −90 −208 −176
Diluted shares — — 9m —
Returned to shareholders
Buybacks 14 — 14 —
Total returned 14 — 14 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $254m
Short-term assets $203mLonger-term assets $51m
What it owes, and who funded it · $254m
Short-term liabilities $31mLonger-term liabilities $1mShareholders' equity $222m
  • Short-term assets cover short-term liabilities $203m of assets due within a year against $31m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $203m short-term assets against $1m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Tonix Pharmaceuticals Holding Corp.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2025 Q4 TTM
Buybacks (TTM)
$13.8M
Returned to shareholders
-13%
of free cash flow
Total shareholder yield
15.9%
dividends 0.0% + buybacks 15.9% of market value
R&D spending
219.4%
of revenue
Sales & admin spending
432.8%
of revenue
Days sales outstanding
148 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated TNXP ARCT GLUE STOK ABEO CRSP Median
Revenue, last 12 months $29m $29m $29m $28m $26m $25m $56m
Revenue growth, last 12 months 196.0% −76.0% −83.9% −86.2% −87.7% −34.3% 12.6%
Revenue growth, 3-year average — −51.9% — 46.1% 212.0% −47.1% 13.7%
Revenue growth, latest quarter 577.9% −89.5% −61.3% −32.5% >999% >999% 10.2%
Gross margin 83.8% — — — 67.1% — 82.9%
Operating margin −568.4% −348.3% −633.0% −809.7% −327.6% <−999% −189.4%
Operating margin, 3-year average −881.2% −154.0% <−999% −515.1% <−999% <−999% −363.5%
Net margin −548.6% −317.6% −560.8% −753.6% −246.4% <−999% −169.8%
Cash from operations / revenue −525.7% −247.7% −83.8% −645.2% −299.5% <−999% −168.0%
Free-cash-flow margin −543.3% −248.0% −111.7% −654.9% −319.5% <−999% −162.4%
Free-cash-flow margin, 3-year average −605.0% −114.9% −424.9% −385.4% <−999% −793.9% −310.0%
Stock pay / revenue 27.3% 71.9% 71.7% 135.7% 45.4% 276.8% 20.0%
Change in share count — 3.5% 11.9% 7.1% 36.6% 10.0% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 196.0% 12.6% 24 of 172
Change in growth rate Growth +121.2pp -0.1pp 18 of 172
Gross margin Profitability 83.8% 82.4% 35 of 75
Operating margin Profitability -568.4% -189.4% 122 of 175
Net margin Profitability -548.6% -157.3% 127 of 180
Free-cash-flow margin Cash generation -543.3% -145.4% 131 of 176
Stock pay as % of revenue Cash generation 27.3% 19.2% 102 of 179
Days sales outstanding Balance sheet 148 days 75 days 86 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Zembrace Symtouch $9.3M 71.1% ▲ 9.0%
Tosymra $2.4M 18.1% ▲ 53.2%
Tonmya $1.4M 10.8% —

From Tonix Pharmaceuticals Holding Corp.'s 10-K filed March 12, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$119M
Institutions reporting
102
Shares held vs prior quarter
▲ 92.3%
Positions opened / closed
28 / 5

Top buyers and sellers, Q2 2026: 79 institutions bought and 13 sold ; the biggest buyer was Point72 Asset Management, L.P (+1.0M shares) and the biggest seller Citadel Advisors LLC (−273K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $17.8M 1.4M 14.9% ▲ 44.4%
Point72 Asset Management, L.P. $14.9M 1.2M 12.5% ▲ 830.3%
Millennium Management LLC $12.3M 967K 10.3% ▲ 340.2%
AQR Capital Management LLC $11.3M 883K 9.4% ▲ 447.5%
Vanguard Capital Management LLC $8.8M 692K 7.4% ▲ 33.4%
Jones Hill Capital LP $8M 625K 6.7% ▲ 38.3%
Geode Capital Management, LLC $5M 395K 4.2% ▲ 26.2%
Ishara Investments LP $4.3M 338K 3.6% New
State Street Corp $3.5M 271K 2.9% ▲ 17.7%
UBS Group AG $3M 232K 2.5% 0.0%
Citadel Advisors LLC $2.5M 196K 2.1% ▼ 58.2%
Essex Investment Management Co LLC $2.1M 165K 1.8% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Tonix Pharmaceuticals Holding Corp.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $458,758 7 trades by 4 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $458,758 net buying
Insider Date Trade Shares Price Value
Lederman Seth Chief Executive Officer August 27, 2026 Buy 2,000 $13.79 $27,580
Bagger Richard H Director August 20, 2026 Buy 1,000 $12.60 $12,600
Taylor Carolyn E. Director June 12, 2026 Buy 1,415 $10.55 $14,928
Lederman Seth Chief Executive Officer June 9, 2026 Buy 5,000 $11.79 $58,950
Stillwell Richard Newcomb Director June 8, 2026 Buy 5,000 $11.65 $58,250
Lederman Seth Chief Executive Officer March 31, 2026 Buy 5,000 $12.62 $63,100
Lederman Seth Chief Executive Officer March 18, 2026 Buy 15,000 $14.89 $223,350

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • October 15, 2026
  • August 10, 2026
  • May 11, 2026
  • May 1, 2026
  • March 13, 2026
  • February 3, 2026

Recent SEC filings

Data status

When each part of this page on Tonix Pharmaceuticals Holding Corp. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Tonix Pharmaceuticals Holding Corp. in brief

What does Tonix Pharmaceuticals Holding Corp. do?
Tonix Pharmaceuticals Holding Corp. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Tonix Pharmaceuticals Holding Corp.'s stock ticker?
Tonix Pharmaceuticals Holding Corp. trades under the ticker TNXP on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Tonix Pharmaceuticals Holding Corp.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Tonix Pharmaceuticals Holding Corp. reported revenue of $29.1M, 196.0% higher than a year earlier, according to its SEC filings.
What is Tonix Pharmaceuticals Holding Corp.'s free cash flow?
Tonix Pharmaceuticals Holding Corp.'s free-cash-flow margin is -543.3% of revenue over the trailing twelve months, ranking 131 of the 176 biotechnology companies we cover.
Who are Tonix Pharmaceuticals Holding Corp.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Point72 Asset Management, L.P. and Millennium Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Tonix Pharmaceuticals Holding Corp.'s market cap?
On December 31, 2025, Tonix Pharmaceuticals Holding Corp.'s market capitalisation was about $133M and net debt of -$208M. Market figures come from third-party market data and may be delayed.
Who are Tonix Pharmaceuticals Holding Corp.'s competitors?
In our Biotechnology peer group, the companies closest to Tonix Pharmaceuticals Holding Corp. are Arcturus Therapeutics Holdings Inc., Monte Rosa Therapeutics, Inc., Stoke Therapeutics, Inc., Abeona Therapeutics Inc. and Crispr Therapeutics AG. The side-by-side comparison below sets their revenue, margins and growth against Tonix Pharmaceuticals Holding Corp.'s.
Are insiders buying or selling Tonix Pharmaceuticals Holding Corp. stock?
Over the last 12 months, Tonix Pharmaceuticals Holding Corp.'s directors and officers reported 7 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Tonix Pharmaceuticals Holding Corp.'s next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Tonix Pharmaceuticals Holding Corp. announces its own schedule.